NVCR Stock Summary and Trading Ideas (Novocure Limited - | NASDAQ:NVCR)

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Novocure Limited - trades on the NASDAQ stock market under the symbol NVCR.

As of April 22, 2024, NVCR stock price declined to $11.83 with 715,938 million shares trading.

NVCR has a beta of 1.52, meaning it tends to be more sensitive to market movements. NVCR has a correlation of 0.04 to the broad based SPY ETF.

NVCR has a market cap of $1.27 billion. This is considered a Small Cap stock.

Last quarter Novocure Limited - reported $134 million in Revenue and -$.45 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.07.

In the last 3 years, NVCR stock traded as high as $232.76 and as low as $10.87.

The top ETF exchange traded funds that NVCR belongs to (by Net Assets): VTI, VB, VXF, VBK, IBB.

NVCR has underperformed the market in the last year with a price return of -81.2% while the SPY ETF gained +22.9%. NVCR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.7% and -16.6%, respectively, while the SPY returned +3.7% and -3.7%, respectively.

NVCR support price is $11.57 and resistance is $12.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVCR stock will trade within this expected range on the day.